Response to Comment on Serés-Noriega et al. Use of the Steno T1 Risk Engine Identifies Preclinical Atherosclerosis Better Than Use of ESC/EASD-2019 in Adult Subjects With Type 1 Diabetes at High Risk. Diabetes Care 2022;45:2412-2421.
暂无分享，去创建一个
[1] J. Vendrell,et al. Comment on Serés-Noriega et al. Use of the Steno T1 Risk Engine Identifies Preclinical Atherosclerosis Better Than Use of ESC/EASD-2019 in Adult Subjects With Type 1 Diabetes at High Risk. Diabetes Care 2022;45:2412-2421. , 2023, Diabetes care.
[2] C. Viñals,et al. Carotid ultrasonography as a strategy to optimize cardiovascular risk management in type 1 diabetes: a cohort study , 2022, Acta Diabetologica.
[3] C. Viñals,et al. Use of the Steno T1 Risk Engine Identifies Preclinical Atherosclerosis Better Than Use of ESC/EASD-2019 in Adult Subjects With Type 1 Diabetes at High Risk. , 2022, Diabetes care.
[4] J. Rocklöv,et al. Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial , 2019, The Lancet.
[5] Steffen E. Petersen,et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2016, European journal of preventive cardiology.